MARKET

LCI

LCI

Lannet Inc
NYSE

Real-time Quotes | Nasdaq Last Sale

0.5266
-0.0034
-0.64%
After Hours: 0.5529 +0.0263 +4.99% 18:23 05/19 EDT
OPEN
0.5546
PREV CLOSE
0.5300
HIGH
0.5700
LOW
0.5010
VOLUME
190.79K
TURNOVER
0
52 WEEK HIGH
5.82
52 WEEK LOW
0.4505
MARKET CAP
22.66M
P/E (TTM)
-0.0664
1D
5D
1M
3M
1Y
5Y
Executives Buy Around $9M Of 4 Penny Stocks
The Nasdaq Composite index jumped by more than 300 points on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors an...
Benzinga · 1d ago
Lannett Company, Inc.'s (NYSE:LCI) recent US$7.2m market cap decline means a loss of US$272k for insiders who bought this year
The recent price decline of 27% in Lannett Company, Inc.'s ( NYSE:LCI ) stock may have disappointed insiders who bought...
Simply Wall St. · 05/12 15:02
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Benzinga · 05/12 12:42
Lannett inks contract with Areva for US distribution of generic version of Bayer's blood cancer drug Fludara
Lannett (NYSE:LCI) signed an agreement with Areva Pharmaceuticals to be the exclusive U.S. distributor of Fludarabine Phosphate for injection, a generic version of Bayer's (OTCPK:BAYRY) (OTCPK:BAYZF) Fludara to treat  chronic lymphocytic leukemia. Trevose,
Seekingalpha · 05/12 11:23
BRIEF-Lannett Enters Agreement To Be Exclusive U.S. Distributor Of Fludarabine Phospate For Injection, USP
reuters.com · 05/12 11:14
LANNETT ENTERS AGREEMENT TO BE EXCLUSIVE U.S. DISTRIBUTOR OF FLUDARABINE PHOSPATE FOR INJECTION, USP
Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Areva Pharmaceuticals to be the exclusive U.S. distributor of Fludarabine Phosphate for injection, USP, 50 mg/2mL, single dose vials.
PR Newswire · 05/12 10:52
Lannett (LCI) Reports Q3 Loss, Lags Revenue Estimates
Lannett (LCI) delivered earnings and revenue surprises of 4.65% and 6.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/04 23:35
Lannett Q3 Adj. EPS $(0.41) Beats $(0.42) Estimate, Adj. EBITDA $98K vs $17M In Same Qtr. Last Year, Sales $78.40M Miss $83.65M Estimate
Lannett (NYSE:LCI) reported quarterly losses of $(0.41) per share which beat the analyst consensus estimate of $(0.42) by 2.38 percent. This is a 2150 percent decrease over earnings of $0.02 per share from the same
Benzinga · 05/04 21:47
More
No Data
Learn about the latest financial forecast of LCI. Analyze the recent business situations of Lannet Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
0.00%Buy
100.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average LCI stock price target is 2.250 with a high estimate of 2.250 and a low estimate of 2.250.
High2.250
Average2.250
Low2.250
Current 0.5266
EPS
Actual
Estimate
-0.37-0.28-0.18-0.09
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
Institutional Holdings
Institutions: 158
Institutional Holdings: 30.48M
% Owned: 70.97%
Shares Outstanding: 43.03M
TypeInstitutionsShares
Increased
19
1.58M
New
12
409.12K
Decreased
25
1.64M
Sold Out
16
1.60M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.15%
Pharmaceuticals & Medical Research
+0.51%
Key Executives
Non-Executive Chairman/Independent Director
Patrick Lepore
Chief Executive Officer/Director
Timothy Crew
Chief Financial Officer/Chief Accounting Officer/Vice President - Finance
John Kozlowski
Chief Operating Officer/Vice President
John Abt
Senior Vice President
Maureen Cavanaugh
General Counsel
Samuel Israel
Director
Jeffrey Farber
Independent Director
John Chapman
Independent Director
David Drabik
Independent Director
Melissa Rewolinski
No Data
No Data
About LCI
Lannett Company, Inc. is a developer, manufacturer, marketer, and distributor of generic versions of brand pharmaceutical products for a range of medical indications. The Company's products include Fluphenazine Tablets, which are used for the management of manifestations of psychotic disorders; Posaconazole DR Tablets, which are used to prevent fungal infections in people; Verapamil SR tablets are a calcium channel blocker used in the treatment of high blood pressure, arrhythmia and angina; Methylphenidate CD Capsules used for the treatment of Attention Deficit Hyperactivity Disorder; Omeprazole Capsules, which is indicated for the treatment of certain diseases of the esophagus and stomach ulcers; Pantoprazole Sodium DR Tablets, which is a proton pump inhibitor, indicated for the treatment of certain diseases of the esophagus and pathological hypersecretory conditions; and Sumatriptan Nasal Spray, which is indicated for the acute treatment of migraine attacks.

Webull offers kinds of Lannett Company, Inc. stock information, including NYSE:LCI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LCI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LCI stock methods without spending real money on the virtual paper trading platform.